On March 17, 2016 OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, reported that new clinical data will be presented at the upcoming American Association of Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting to be held on April 16-20, 2016 in New Orleans, LA (Press release, OncoSec Medical, MAR 17, 2016, View Source [SID:1234509604]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
This new data relates to the Company’s Phase II monotherapy clinical study of its investigational intratumoral plasmid IL-12 with electroporation (IT-pIL12-EP) in patients with melanoma. After completing treatment with IT-pIL12-EP, a subset of patients subsequently received anti-PD-1/PD-L1 therapies. Patients with documented follow-up history and evaluable for anti-PD-1/PD-L1 response were included in this single-site retrospective analysis.
Details of the presentation are as follows:
Abstract Title: Intratumoral electroporation of plasmid IL-12 can prime response to anti-PD1/PD-L1 blockade in patients with Stage III/IV-M1a melanoma (Abstract #CT134)
Session Title: Early Clinical Trials Evaluating Cell-based Checkpoint Inhibitors and Novel Immunotherapeutics
Date and Time: April 19, 2016 at 3:45 – 4:00 PM
Location: Room 343, Morial Convention Center